论文部分内容阅读
目的探讨紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗头颈部肿瘤的临床疗效。方法选取2012年12月至2015年12月间安徽医科大学附属巢湖医院收治的96例头颈部肿瘤患者为研究对象,采用随机数表法分为观察组(采用紫杉醇脂质体联合卡铂)与对照组(采用紫杉醇联合卡铂),每组48例。比较两组患者化疗结束后临床疗效、自然杀伤(NK)细胞活性和不良反应发生情况。结果化疗结束后,观察组患者临床治疗有效率和疾病控制率分别为45.8%和81.3%;对照组患者临床治疗有效率和疾病控制率分别为31.3%和72.9%,两组组间比较,差异均无统计学意义(均P>0.05)。观察组患者NK细胞活性高于对照组患者,差异有统计学意义(P<0.05)。观察组患者Ⅲ级和Ⅳ级不良反应发生率分别为10.4%和2.1%,低于对照组患者的20.8%和10.4%,差异有统计学意义(P<0.05)。结论紫杉醇脂质体相较紫杉醇治疗头颈部肿瘤疗效更好,对NK细胞活性影响更小,不良反应更低。
Objective To investigate the clinical efficacy of paclitaxel liposome combined with carboplatin and paclitaxel combined with carboplatin in the treatment of head and neck cancer. Methods A total of 96 patients with head and neck cancer who were treated in Chaohu Hospital affiliated to Anhui Medical University from December 2012 to December 2015 were selected as study objects. The patients were divided into observation group (using paclitaxel liposome combined with carboplatin) And control group (with paclitaxel combined with carboplatin), 48 cases in each group. The clinical efficacy, natural killer (NK) cell activity and adverse reactions were compared between the two groups after chemotherapy. Results After the chemotherapy, the effective rate of clinical treatment and the rate of disease control in the observation group were 45.8% and 81.3% respectively. The clinical effective rate and disease control rate in the control group were 31.3% and 72.9% respectively. There was significant difference between the two groups No statistical significance (all P> 0.05). NK cell activity in observation group was higher than that in control group, the difference was statistically significant (P <0.05). The incidences of grade Ⅲ and Ⅳ adverse reactions in the observation group were 10.4% and 2.1%, respectively, which were lower than those in the control group (20.8% and 10.4%, P <0.05). Conclusion Paclitaxel liposomes are more effective than paclitaxel in the treatment of head and neck tumors, and have less impact on NK cell activity and lower adverse reactions.